Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05266248 · ClinicalTrials.gov registry record · Phase 1
Pilot Study Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage in the Fed and Fasted States
A Phase 1 study of Pharmacokinetics, sponsored by PepsiCo Global R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05266248: Completed Phase 1 study of Pharmacokinetics, sponsored by PepsiCo Global R&D.
NCT05266248 is a Phase 1 study of Pharmacokinetics that has completed, run by PepsiCo Global R&D. The registered enrollment target is 18 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05266248, a Phase 1 study of Pharmacokinetics, has completed, sponsored by PepsiCo Global R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Pilot study designed to characterize the plasma caffeine pharmacokinetic profile of encapsulated caffeine when consumed in the fasted and fed states.
Primary Outcome
Plasma caffeine pharmacokinetics
Conditions Studied
Interventions
- OTHER 250 mg encapsulated caffeine
Study Locations (1)
Florida
- GCP Research - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2022-02-03 |
| Phase | Phase 1 |
What the finished NCT05266248 record still lists
NCT05266248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention - of which 250 mg encapsulated caffeine is the first listed.
NCT05266248 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05266248 about?
NCT05266248 is a clinical study titled "Pilot Study Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage in the Fed and Fasted States". Pilot study designed to characterize the plasma caffeine pharmacokinetic profile of encapsulated caffeine when consumed in the fasted and fed states.
What is the current status of trial NCT05266248?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-01-25. Estimated completion is 2022-02-03.
What conditions does trial NCT05266248 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT05266248?
The interventions under investigation include: 250 mg encapsulated caffeine (OTHER).
Who is sponsoring clinical trial NCT05266248?
This trial is sponsored by PepsiCo Global R&D, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05266248 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05266248's enrollment target sits among peer trials
18 27th of 37 higher than 9 of 37 other Pharmacokinetics trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pharmacokinetics trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI